NeuroGlow Press & News
Discover the latest press releases, media coverage, and company news from NeuroGlow, a leader in brain health and cognitive wellness innovation. Explore how NeuroGlow is shaping the future of neuroscience-driven solutions through research-backed products, expert insights, and strategic advancements in mental performance, neurotechnology, and holistic brain care.
About Us
Meet NeuroGlow’s mission, values, and team plus how we deliver clinician-led ketamine therapy with compassion, privacy, and consistency. From intake onward.
Why NeuroGlow
See what makes NeuroGlow different, including screening, clinician monitoring and personalized plans designed to support lasting progress for you today too.
Insights & Articles
Explore evidence informed articles on ketamine therapy, mood disorders and integration practices that help build resilience between visits at home as well.
Press Updates
North Texas is seeing a surge in ketamine clinics as more people look for faster mental health relief. At the same time, Texas is exploring broader psychedelic therapies.
- January 19, 2026
For Reese Ormand, the path to building a mental health clinic in North Texas did not begin as a business idea. It began after closing one chapter of his career and confronting the personal cost of another.
- January 19, 2026
The Lone Star State is home to $50 million in legislative funding for psychedelic research, a former governor who is a psychedelic advocate, and a growing infusion market
- December 23, 2025
Psilocybin may help prevent chemo-induced nerve pain, as Definium earns its second FDA Breakthrough Therapy designation. Read the updates.
- Sep 12, 2026
Take a closer look inside a Tarrant ketamine clinic, explore the business behind its operations, and learn what its owners are planning next.
- Oct 09, 2026
Latest News
‘Ketamine Queen’ Jasveen Sangha Sentenced to 15 Years in Death of Matthew Perry Case
The ‘Ketamine Queen’ has been sentenced to 15 years in prison for supplying the drug that killed Friends star Matthew Perry. Jasveen Sangha’s sentencing closes the central chapter of a case that brought down five defendants, including two doctors and Perry’s own personal assistant.
Reading Spravato’s Package Insert, Now That It Can Be Used on Its Own
Spravato, the nasal spray form of esketamine, has been a closely watched treatment for adults with treatment-resistant depression since the drug was first approved in the United States in 2019.
Spravato, the Ketamine Derived Nasal Spray, and the Company That Makes It
Spravato, a prescription nasal spray used to treat some severe forms of depression, is manufactured for Janssen Pharmaceuticals, Inc., a Johnson & Johnson company.